Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency (CITT-ART)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02207517 |
Recruitment Status : Unknown
Verified March 2020 by Mitchell Scheiman, Salus University.
Recruitment status was: Active, not recruiting
First Posted : August 4, 2014
Last Update Posted : March 17, 2020
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Convergence Insufficiency | Procedure: Office-based vergence/accommodative therapy | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 311 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART) |
Actual Study Start Date : | May 2014 |
Actual Primary Completion Date : | July 2017 |
Estimated Study Completion Date : | November 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Office-based verg/accomm therapy (OBVAT)
OBVAT requires a participant to undergo a specific vision therapy regimen with 16 weekly, 60-minute in-office treatment sessions. Vision Therapists (O.D., M.D., Orthoptists, or specially-trained technicians) administer the therapy in the office. OBVAT procedures are then supplemented with various home therapy procedures
|
Procedure: Office-based vergence/accommodative therapy
The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
Other Names:
|
Placebo Comparator: Office-based placebo therapy (OBPT)
Office-based Placebo Therapy (OBPT) requires a participant to undergo a specific therapy regimen of 16 weekly, 60 minute, in-office treatment sessions. Vision therapists (optometrists, ophthalmologists, orthoptists, or specially-trained technicians) administer the therapy in the office. OBPT procedures are then supplemented with placebo home therapy procedures. The procedures for OBPT are designed with the intent of not providing a beneficial training effect on vergence, accommodation, saccadic accuracy, or visual attention beyond normal activities. However, the procedures are designed to simulate real vision therapy in such a way that it will be difficult for participants and parents to know that they have been assigned to the control group and thus are not receiving bonafide OBVAT |
Procedure: Office-based vergence/accommodative therapy
The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
Other Names:
|
- The change in the Wechsler Individual Achievement Test-III (WIAT-III) reading comprehension score as measured after the completion of 16 weeks of assigned treatment (OBVAT or OBPT). [ Time Frame: After 16 weeks of treatment ]This test requires the examinee to respond to multiple-choice questions after having read passages independently.
- The change in the Strengths and Weaknesses of ADHD Symptoms and Normal Behavior Scale (SWAN) [ Time Frame: After 16 weeks of treatment ]The SWAN is a behavior rating scale that has been used for many years as an assessment tool for ADHD.
- Gates-McGintie 4 [ Time Frame: After 16 weeks of treatment ]The child must respond to multiple-choice questions after having read passages independently
- d2 Test of Attention [ Time Frame: After 16 weeks of treatment ]The d2 is a timed test of selective and sustained attention.The test measures processing speed, rule compliance, and quality of performance in response to the discrimination of similar stimuli, thereby allowing for an estimation of individual attention and concentration performance
- Academic Behavior Survey (ABS) [ Time Frame: After 16 weeks of treatment ]The ABS is a 6-item survey designed to measure the frequency of adverse academic behaviors and parental worry about academic performance.
- Curriculum Based Measurement (CBM) [ Time Frame: After 16 weeks of treatment ]Curriculum Based Measurement is commonly used by educators to assess short-term progress in reading, skills as the child proceeds through the academic year The primary advantage of the CBM measure is the ability to track rate of improvement by initial reading level and by time of year. The addition of the CBM measure will assess reading at each outcome visit and allow us to track changes in a similar manner to attention and CI where we have measures at each outcome visit. In addition, CBM will provide an additional outcome measure for reading using a method that is commonly employed by school districts to monitor reading progress and will help to communicate the clinical significance of our results.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 9 Years to 13 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 9 to less than 14 years
- Grades 3 through 8
- CI Symptom Survey (CISS) score greater or equal to 16
- Exophoria at near at least 4 prism diopters greater than at far
- Receded near point of convergence (NPC) of 6 cm or greater break
- Insufficient positive fusional vergence (PFV) at near (i.e., failing Sheard's or PFV less than or equal to 15 BO break)
- Best-corrected distance visual acuity of 20/25 or better in each eye
- Random dot stereopsis appreciation of 500 seconds of arc or better
-
Wearing appropriate refractive correction (spectacles or contact lenses) for at least 2 weeks prior to final determination of eligibility for any of the following uncorrected refractive errors (based on cycloplegic refraction within prior 12 months)
- Myopia greater than -0.75D spherical equivalent (SE) in either eye
- Hyperopia greater than +2.00D SE in either eye
- SE anisometropia greater than 0.75D
- Astigmatism greater than 1.00D in either eye
Correction for patients meeting above refractive error criteria must meet the following guidelines:
- SE anisometropia must be within 0. 75D of the full anisometropic correction
- Astigmatism must be within 0.75D of full correction; axis must be within 6◦ if astigmatism greater than or equal to 1.00D
- For hyperopia, the sphere can be reduced by up to 1.50 D provided reduction is symmetrical
- For myopia, the SE must be within 0.75D of the full myopic correction
- No use of BI prism or plus add at near for 2 weeks prior to study and for duration of study
- English is primary language spoken at home or child proficient in English as determined by the school
- Parent does not expect child to start any new ADHD medicine or change the dose of any currently taken ADHD medicine while child is being treated in the study
- Parental permission to contact the child's teacher(s) for study purposes
- Parent and child understand protocol and are willing to accept randomization
Exclusion Criteria:
- Constant strabismus at distance or near
- Esophoria of greater than or equal to 2∆ at distance
- Vertical heterophoria greater than or equal to 2∆ at distance or near
- greater than or equal to 2 line interocular difference in best-corrected distance visual acuity
- Monocular near point of accommodation greater than 20 cm (accommodative amplitude less than 5D) in right eye
- Manifest or latent nystagmus
- Word Reading subtest score less than 80 on the Wide Range Achievement Test (WRAT-4)
- Kaufman Brief Intelligence Test (KBIT-2) Matrices subtest score less than 70
- History of prior strabismus, intraocular, or refractive surgery
- CI previously treated with any form of office-based vergence/accommodative therapy or home-based vergence therapy (e.g., computerized vergence therapy)
- CI associated with head trauma or known disease of the brain
- Diseases known to affect accommodation, vergence, or ocular motility
- Inability to comprehend and/or perform any study-related test or therapy procedure
- Speech-language disorder (e.g., stuttering) that would interfere with interpretation of digital recordings of reading tests
- Significant hearing loss
- Household member enrolled in present CITT-ART, treated currently, or treated within the past 6 months with any form of office-based vergence/accommodative therapy or home-based vergence therapy (e.g., computerized vergence therapy)
- Parent or other household member is an eye care professional, ophthalmic technician, ophthalmology or optometry resident, or optometry student

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02207517
United States, Alabama | |
University of Alabama, Birmingham College of Optometry | |
Birmingham, Alabama, United States, 35294 | |
United States, California | |
Southern California College of Optometry Marshall B. Ketchum University | |
Fullerton, California, United States, 90037 | |
United States, Florida | |
NOVA Southeastern University College of Optometry | |
Fort Lauderdale, Florida, United States, 33314 | |
Bascom Palmer Eye Institute | |
Miami, Florida, United States, 33136 | |
United States, New York | |
State University of Optometry College of Optometry | |
New York, New York, United States, 10036 | |
United States, Ohio | |
Akron Children's Hospital | |
Akron, Ohio, United States, 44302 | |
Ohio State University College of Optometry | |
Columbus, Ohio, United States, 43210 | |
United States, Pennsylvania | |
Pennsylvania College of Optometry at Salus University | |
Philadelphia, Pennsylvania, United States, 19141 |
Study Chair: | Mitchell Scheiman, OD | Salus University | |
Principal Investigator: | Lynn MItchell, MAS | Ohio State University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Mitchell Scheiman, Dean of Research, Salus University |
ClinicalTrials.gov Identifier: | NCT02207517 |
Other Study ID Numbers: |
Salus - HMS1310 U10EY022599-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | August 4, 2014 Key Record Dates |
Last Update Posted: | March 17, 2020 |
Last Verified: | March 2020 |
convergence insufficiency vision therapy reading attention |
Ocular Motility Disorders Central Nervous System Diseases Nervous System Diseases Cranial Nerve Diseases Eye Diseases |